Article Per Year (5 Year)
p-Index From 2021 - 2026
2.407
P-Index
This Author published in this journals
All Journal HAYATI Journal of Biosciences Farmaka Dharmakarya : Jurnal Aplikasi Ipteks Untuk Masyarakat Indonesian Journal of Pharmaceutical Science and Technology Jurnal Farmasi Klinik Indonesia Pharmauho: Jurnal Farmasi, Sains, dan Kesehatan The Indonesian Biomedical Journal Molecular and Cellular Biomedical Sciences (MCBS) Current Research on Biosciences and Biotechnology Indonesian Journal of Biological Pharmacy Sciences of Pharmacy Public Health Risk Assesment Journal
Melisa Intan Barliana, Melisa Intan
Unknown Affiliation
Agriculture, Biological Sciences & Forestry Arts Humanities Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Computer Science & IT Dentistry Earth & Planetary Sciences Economics, Econometrics & Finance Engineering Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Materials Science & Nanotechnology Medicine & Pharmacology Neuroscience Public Health Veterinary

Published : 17 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 17 Documents
Search

 1   2 
ERCC2 rs13181 and ERCC1 rs11615 polymorphisms in non-small cell lung cancer patients in West Java: towards personalized medicine approaches Afifah, Nadiya Nurul; Effendi, M. Fariz; Diantini, Ajeng; Barliana, Melisa Intan; Intania, Ruri
Current Research on Biosciences and Biotechnology Vol. 6 No. 2 (2025)
Publisher : Institut Teknologi Bandung

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.5614/crbb.2025.6.2/3DCBQ451

Abstract

Non-Small Cell Lung Cancer (NSCLC) is a disease with a high incidence rate, low survival due to late diagnosis and treatment delays, and varying effectiveness of platinum-based chemotherapy. Individual responses to platinum-based chemotherapy are influenced by genetic polymorphisms in genes affecting pharmacokinetic and pharmacodynamic mechanisms. This study focuses on identifying polymorphisms in the ERCC2 and ERCC1 genes, which play a role in platinum pharmacodynamics, and their effects on chemotherapy response. The study involved 23 NSCLC patients conducted at Dr. H.A. Rotinsulu Lung Hospital in Bandung. Polymorphism data were obtained through genotype analysis using sequencing methods from prospective whole blood samples of patients, while chemotherapy effectiveness was assessed by evaluating chemotherapy response using the RECIST 1.1 method, and radiological response prediction and prognostic factors were determined through CYFRA 21-1 levels. The results showed an OR of 0.964 (95% CI: 0.160 - 5.795) for ERCC2 rs13181 CC + AC vs. AA against chemotherapy response evaluation by RECIST 1.1, and 0.722 (95% CI: 0.062 - 8.464) against CYFRA 21-1 values. Meanwhile, for ERCC1 rs11615, an OR of 0.268 (95% CI: 0.046 - 1.548) CT + TT vs. CC for RECIST 1.1 and 0.3 (95% CI: 0.026 - 3.427) for CYFRA 21-1 values were obtained. In clinical interpretation, it is known that variant alleles at rs13181 and rs11615 have potential for better chemotherapy response although not statistically significant (p>0.05), these results can be considered when assessing patient response to chemotherapy within six cycles. This study provides initial data and forms the basis for future comprehensive cohort observational research.
Characterization of Lactococcus garvieae Isolated from Wadi Papuyu (Anabas testudineus Bloch) Fermentation of Indonesian Origin as a Probiotic Candidate Soemarie, Yulistia Budianti; Pratama, Rizki Rahmadi; Milanda, Tiana; Barliana, Melisa Intan
Sciences of Pharmacy Volume 4 Issue 2
Publisher : ETFLIN Publishing House

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.58920/sciphar0402317

Abstract

Lactococcus garvieae was isolated from the traditional fermented food Wadi Papuyu (Anabas testudineus Bloch) and characterized for its potential as a probiotic candidate. Growth assays demonstrated that L. garvieae could proliferate in MRS medium, reaching cell counts exceeding 107 CFU/mL after 72 h of anaerobic incubation. The isolate exhibited optimal growth at both 30 °C and 37 °C, as indicated by significant increases in absorbance at these temperatures. However, in the bile salt tolerance test using 0.5% (w/v) bile salts, L. garvieae showed a marked decline in growth, with absorbance values decreasing substantially after 24 and 48 h, indicating insufficient bile tolerance. The autoaggregation assay revealed values below 10%, suggesting limited autoaggregation capability and reduced potential for colonization in the gastrointestinal tract. In contrast, the co-aggregation assay showed that L. garvieae was able to coaggregate with pathogenic bacteria such as Escherichia coli, Salmonella spp., and Shigella spp., with co-aggregation percentages exceeding 40% after 5 h. Antimicrobial activity tests demonstrated that L. garvieae produced strong inhibition zones (diameters >10–20 mm and >20 mm) against Gram-positive and Gram-negative pathogenic bacteria. These findings indicate that while L. garvieae exhibits promising antimicrobial activity and co-aggregation ability, its limited bile salt tolerance and autoaggregation capacity are significant constraints in its development as a probiotic candidate.
Optimizing diabetic retinopathy therapy with precision medicine: Can we do that in Indonesia? Putri, Nazwa Septiriana; Barliana, Melisa Intan
Public Health Risk Assesment Journal Vol. 3 No. 1: July (2025)
Publisher : Institute for Advanced Science, Social, and Sustainable Future

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.61511/phraj.v3i1.2025.1840

Abstract

Background: Diabetes is one of the most common diseases in the world, including in Indonesia. High blood sugar levels in diabetics can cause various complications, one of which is diabetic retinopathy. The treatment used in diabetic retinopathy does not fully provide the desired therapeutic effect in all patients. Therefore, a study was conducted on the prescription drug approach to optimize diabetic retinopathy therapy. Methods: This narrative review was conducted by searching articles that discuss three main focuses, including (1) why precision medicine (PM) can be implemented in diabetic retinopathy (DR); (2) the application, benefits, and components of PM for DR; and (3) challenges in its implementation in Indonesia. The included articles are articles published in national and international journals between 2014 and 2025. Findings: This study reveals that diabetic retinopathy is a complication of diabetes whose development can be influenced by genetic and environmental factors of the patient. Precision medicine can be applied in determining the best therapy for diabetic retinopathy by analyzing the clinical condition history, molecular and biochemical biomarkers of patients using artificial intelligence or machine learning. Conclusion: optimization of diabetic retinopathy therapy can be done with a precision medicine approach by analyzing genetic factors and patient environmental factors. However, there are still some challenges in its application in Indonesia including health service disparities, regulatory issues, technology, costs, and human resources. To develop precision medicine in Indonesia, Indonesia should develop equitable distribution in health services, conduct policy and research more on DM and PM, and collaborate with other countries. This narrative review has several limitations: literature search was limited to 3 database sources, we did not assess the quality of the articles, and implementation steps and solutions for PM implementation in Indonesia are only discussed in general, not specifically for DR. Future research can be carried out by discussing in more depth the specific steps of PM implementation for DR. Novelty/Originality of this article: Although personalized medicine has been in the spotlight in the global. Novelty/Originality of this article: Although personalized medicine has been in the spotlight in the global medical world, its specific application in the treatment of diabetic retinopathy in a country with limited resources and diverse demographics such as Indonesia is still not widely explored. The originality lies in adapting precision medicine as a high-tech solution for diabetic retinopathy, which is one of the public health challenges.
Analisis Efektivitas Biaya Penggunaan Antipsikotik Tipikal (Haloperidol) dan Atipikal (Risperidon) pada Pasien Skizofrenia di RSUP Dr. Hasan Sadikin Bandung Syahrina, Nadira Alvi; Barliana, Melisa Intan; Zakiyah, Neily; Iskandar, Shelly
Indonesian Journal of Clinical Pharmacy Vol 13, No 2 (2024)
Publisher : Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15416/ijcp.2024.13.2.61455

Abstract

Skizofrenia merupakan gangguan mental kronis yang membutuhkan terapi jangka panjang serta melibatkan biaya perawatan kesehatan yang besar. Penelitian ini bertujuan untuk menganalisis efektivitas biaya antara penggunaan risperidon dibandingkan dengan haloperidol pada terapi skizofrenia, serta menganalisis faktor utama yang memengaruhi nilai efektivitas biaya pada rawat inap di RSUP Dr. Hasan Sadikin Bandung (RSHS) pada 2017–2018. Data dikumpulkan secara retrospektif dari perspektif penyedia layanan kesehatan, mencakup total biaya medis langsung baik yang ditanggung rumah sakit maupun oleh Badan Penyelenggara Jaminan Sosial (BPJS). Nilai efektivitas diukur dalam penurunan penurunan skor PANSS. Hasil menunjukkan bahwa nilai average cost-effectiveness ratio (ACER) risperidon adalah Rp527.002 per satuan penurunan PANSS, sedangkan haloperidol Rp357.374. Berdasarkan perhitungan incremental cost-effectiveness ratio (ICER), haloperidol menunjukkan nilai Rp486.809 per satuan penurunan PANSS dibandingkan risperidon. Meskipun ICER haloperidol lebih tinggi dari risperidon, hasil tersebut masih berada dalam ambang batas willingness to pay yang ditetapkan di Indonesia (berdasarkan 1–3 kali PDB per kapita), sehingga terapi haloperidol dapat dikategorikan sebagai cost-effective. Dari sisi efisiensi biaya, haloperidol menghasilkan penghematan sekitar Rp378.737 dibandingkan risperidon. Dengan demikian, terapi haloperidol lebih dominan secara ekonomi dan layak dipertimbangkan sebagai pilihan pengobatan yang lebih efisien bagi pasien skizofrenia rawat inap di RSHS Bandung.
ABCB1 rs1045642 Genotypes and Clinical Response in Indonesian Patients with Systemic Lupus Erythematosus Pratama, Muhammad Syawal; Afifah, Nadya Nurul; Permatasari, Lany Indah; Kennardi, Gabriel Bagus; Hamijoyo, Laniyati; Sahiratmadja, Edhyana; Barliana, Melisa Intan
Indonesian Journal of Clinical Pharmacy Vol 13, No 3 (2024)
Publisher : Universitas Padjadjaran

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.15416/ijcp.2024.13.3.62273

Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease often managed with immunosuppressants such as methylprednisolone (MP) and azathioprine (AZA), although therapeutic responses vary among individuals. Genetic variation, including polymorphisms in the ATP-Binding Cassette Subfamily B Member 1 (ABCB1) gene encoding the P-glycoprotein drug transporter, may influence treatment outcomes. The rs1045642 polymorphism has been linked to variable responses in SLE, but data in Indonesian populations are scarce. This study aimed to describe the distribution of the ABCB1 rs1045642 polymorphism in SLE patients from Bandung, Indonesia, and to explore its potential association with therapy outcomes using MP and/or AZA. We conducted a cross-sectional study of 84 SLE patients, collecting clinical data from medical records. Treatment outcome was defined as achievement of lupus low disease activity state (LLDAS). Genomic DNA was extracted and sequenced to determine rs1045642 genotypes. A total of 84 SLE patients were included, predominantly aged 26–35 years (34%). Almost half had a disease duration of 6–10 years (49%). The majority achieved LLDAS (69%), and all patients were receiving methylprednisolone, with 78.6% also receiving azathioprine. The genotype distribution of ABCB1 rs1045642 was AA 10.71%, AG 61.91%, and TT 27.38%, which deviated from Hardy–Weinberg equilibrium (p < 0.05). However, genetic variations were observed among patients with SLE. Further studies on other possible polymorphisms related to the outcome of SLE therapy are needed.
Anticancer Activities and Metabolite Profiling of UHPLC-HRMS Method from Chrysanthemum x morifolium (Ramat.) Hemsl Leaves Maesaroh, Imas; Barliana, Melisa Intan; Abdulah, Rizky; Muhaimin, Muhaimin
HAYATI Journal of Biosciences Vol. 33 No. 1 (2026): January 2026
Publisher : Bogor Agricultural University, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.4308/hjb.33.1.167-180

Abstract

The Chrysanthemum morifolium Ramat, traditionally used for cancer treatment, including breast cancer, possesses anticancer properties. The aim of this study is metabolite profiling using ultra-high-performance liquid chromatography in conjunction with the high-resolution mass spectrometry (UHPLC-HRMS) technique and its correlation with the cytotoxic activity of the extract and ethyl acetate fraction of Chrysanthemum x morifolium (Ramat.) Hemsl leaves on cancer cells. The ethyl acetate fraction from the hydrolyzed ethanol extract of (Chrysanthemum x morifolium (Ramat.) Hemsl) leaves has anticancer activity against the MCF-7 breast cancer cells. Metabolite profiling was used to understand the presence of metabolites that have anticancer activity. UHPLC-HRMS was used to profile their metabolites. Compound Discoverer 3.3 software finished data processing and metabolite annotation. Anticancer activity was performed using the 2-[2-methoxy-4-nitrophenyl]-3[4-nitrophenyl]-5[2,4-disulfophenyl]-2H-tetrazolium (WST-8) assay. As many as 57 secondary metabolites were identified by UHPLC-HRMS analysis. Secondary metabolites that have the potential as anti-breast cancer are glycitein, diosmetin, kaempferol, esculetin, scopoletin, dihydroartemisinin, and Chrysin, with successive percentages of 31.39%, 19.91%, 5.61%, 2.63%, 0.82%, 0.14%, and 0.05%. Ethyl acetate fraction showed stronger cytotoxic activity than ethanol extract against MCF-7 cells with IC50 values of 66.31 ppm at 24 hours incubation and 40.35 ppm at 48 hours. Further research can be conducted on the isolation of flavonoids from the ethyl acetate fraction, as well as the analysis of cell cycle apoptosis stimulation and gene expression mechanisms.
B Cell-Activating Factor (BAFF) and Ubiquitin Enzyme A20 as Functional Proteins in Targeted Therapy on Patients with Systemic Lupus Erythematosus Fajar, Desi Reski; Rostinawati, Tina; Hamijoyo, Laniyati; Barliana, Melisa Intan
The Indonesian Biomedical Journal Vol 16, No 5 (2024)
Publisher : The Prodia Education and Research Institute (PERI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.18585/inabj.v16i5.3161

Abstract

BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by inflammation. The pathogenesis of SLE involves key proteins, including B cell-activating factor (BAFF) and the ubiquitin enzyme A20, both serving as negative regulators of inflammation and contributing to B cell homeostasis. In this review, focused on interventions directed at BAFF and the A20 enzyme, utilizing monoclonal antibodies either independently or in conjunction with conventional therapy for SLE patients.METHODS: A literature search was conducted on the PubMed platform by combining various terms, including "B-cells activating factor", "TNFAIP3 protein (human)", "therapeutics" or "drug therapy", and "lupus erythematosus, systemic" (limited to the last 10 years). From total of 104 articles discovered in thr search, the total number of articles collected after being filtered was 27 articles.RESULTS: Clinical development and evaluation have been conducted regarding the use of appropriate therapy for SLE patients. Selective BAFF inhibitor has been tested in clinical trials as a blocking agent in BAFF receptor (BAFF-R) and signaling nuclear factor-kappaB (NF-κB) by A20 bindings to inhibit the activation of autoreactive B cells. Just like other antimonoclonal therapies, BAFF and the A20 enzyme can be used as therapeutic targets with a single use or combined with the standard therapy in patients with SLE. In addition, the use of BAFF and A20 also shown to have safe side effects in patients with SLE. CONCLUSION: BAFF protein and A20 enzyme present promising therapeutic targets for managing autoimmune diseases like SLE. Therapeutic interventions can be administered individually or in conjunction with standard treatments.  KEYWORDS: systemic lupus erythematosus, therapeutic targets, BAFF, A20
Co-Authors Afifah, Nadya Nurul Ahmad Faried Ahmad Muhtadi Ajeng Diantini, Ajeng Among, Sayyid ANDI WIJAYA Angliana Chouw, Angliana ARNANDA, QUINZHEILLA PUTRI Balqist, Syara Nur Fitri Bonor, Toga Cynthia Retna Sartika, Cynthia Retna Driyanti Rahayu Edhyana Sahiratmadja Effendi, M. Fariz Eva Feriadi Fajar, Desi Reski Haifa, Rima Imas Maesaroh Indradi, Raden Bayu Intania, Ruri Irma Melyani Puspitasari Kennardi, Gabriel Bagus Khaira, Syifa Laniyati Hamijoyo, Laniyati Maisyarah, Intan Timur Muhaimin Muhaimin Mustikawati, Bunga Nadiya Nurul Afifah Peratiwi, Shafira Galuh Permatasari, Lany Indah Pratama, Muhammad Syawal Putri Maharani Putri, Nazwa Septiriana Qolbina, Shofura Marsa Raden Maya Febriyanti Rendrayani, Farida Rimadani Pratiwi Rizky Abdulah Sahila, Elma N. M. R. Shelly Iskandar Soemarie, Yulistia Budianti Syahrina, Nadira Alvi Tahara, Nabila TIANA MILANDA Tina Rostinawati Yuni Elsa Hadisaputri Zakiyah, Neily